Leerink Swann Initiates ACADIA Pharmaceuticals At Outperform

Analysts at Leerink Swann initiated coverage on ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD) with a Outperform rating.

The target price for ACADIA Pharmaceuticals is set to $48.

ACADIA Pharmaceuticals shares have gained 92.90% over the past 52 weeks, while the S&P 500 index has surged 12.97% in the same period.

ACADIA Pharmaceuticals shares rose 1.33% to $38.00 in pre-market trading.